Adial Pharmaceuticals (ADIL) Receivables (2024 - 2025)
Adial Pharmaceuticals (ADIL) posted Receivables of $41758.0 for Q4 2025, down 25.46% sequentially from $56020.0 in Q4 2024, and down 25.46% YoY from $56020.0 in Q4 2024.
Adial Pharmaceuticals (ADIL) Receivables (2024 - 2025) Analysis & Trends
Adial Pharmaceuticals has reported Receivables for 2 years, with the latest figure at $41758.0 in Q4 2025.
- Quarterly Receivables fell 25.46% year-over-year to $41758.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41758.0 (down 25.46% YoY) and the FY2025 annual result came in at $41758.0, down 25.46% from the prior year.
- Receivables eased to $41758.0 in Q4 2025 per ADIL's latest filing, from $56020.0 in the prior quarter.
- Over five years, Receivables peaked at $56020.0 in Q4 2024 and troughed at $41758.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Adial Pharmaceuticals | 27.94 Mn | 27.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41,758.00 |
| Dec 31, 2024 | 56,020.00 |